Insulet Corporation Earnings Recaps
Q1 2026
May 8, 2026
Shares declined 4.3% after Insulet’s earnings call as investors reacted negatively to a cautious outlook shaped by seasonal headwinds in the U.S. diabetes market and modest deceleration in early-year revenue trends, despite raised full-year guidance.
Key takeaways
- Reported 30% revenue growth in Q1 2026, including 28% growth in the U.S. and 45% internationally.
- Adjusted operating margin expanded by 110 basis points year-over-year, driving roughly 40% adjusted EPS growth.
- Management cited unusual seasonality effects from annual insurance deductible resets, causing a slower start in U.S. market demand.
- Though full-year revenue growth guidance was slightly raised to 21–23%, early quarter softness and cautious tone on U.S. trends weighed on sentiment.
- Continued progress internationally with strong new customer starts and expanded reimbursement coverage, particularly in Canada and Europe.
Q3 2025
Nov 7, 2025
Insulet Corporation delivered a remarkable third quarter in 2025, achieving over $700 million in revenue, reflecting a 28% year-over-year growth, driven by strong customer retention and expansion in both Type 1 and Type 2 markets.
Key takeaways
- Surpassed $700 million in quarterly revenue for the first time, demonstrating the strength of its recurring revenue model.
- Operating margins increased by 90 basis points to 17.1%, reflecting efficient cost management alongside investments in innovation.
- New customer starts in the U.S. Type 2 market more than doubled year-over-year, highlighting strong momentum and effective outreach strategies.
- International revenue grew 40% year-over-year, driven by successful global launches, including Omnipod 5, and strong demand in established markets.
- The expanded leadership team aims to further enhance Insulet's market position and customer experience across various segments.